News | April 13, 2026
Unichem’s US arm recalls Buspirone tablets after stability test OOS result
No adverse events reported; recall involves 5 mg 500-count bottles in the US market
No adverse events reported; recall involves 5 mg 500-count bottles in the US market
Routine regulatory filing confirms completion of demat and share transfer compliances for March quarter
Both ordinary resolutions sail through with over 99.6% votes in favour, strengthening leadership continuity at the drugmaker
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
API maker begins circulation of second and final call money notice for partly paid-up rights shares, completing the last leg of its 2024 fundraising cycle
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually
The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701
Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
Subscribe To Our Newsletter & Stay Updated
